VIRO ViroGates

Minutes of Annual General Meeting 2019

Minutes of Annual General Meeting 2019

Company announcement no. 6-2019

Birkerød, 25 April 2019

Minutes of annual general meeting 2019 in Virogates A/S, CVR-no 25 73 40 33 (“Virogates”).

Today, 25 April 2019, an annual general meeting was held in ViroGates at Comwell Holte, Kongevejen 495A, 2840 Holte. Reference is made to company announcement no. 4-2019 of 8 April 2019 setting out the agenda and complete proposals.

The following resolutions were passed:

  1. Attorney-at-law Nicolai Jung was elected chairman of the general meeting.
  2. The annual report with auditors’ report for the financial year 2018 was adopted.
  3. It was resolved to transfer the loss for the financial year 2018 of DKK 16,986,212 to the next year.
  4. All current members of the board of directors were re-elected. It was resolved that the remuneration for the work of the board in 2019 will be fixed at DKK 150,000 to the chairman and DKK 75,000 to each of the other directors.
  5. BDO Statsautoriseret Revisionsaktieselskab was re-elected as auditor. 

For further information contact:

CEO Jakob Knudsen

Tel. (+45) 2113 1336, Email:

ViroGates A/S

CVR-nr. 25734033

Blokken 45, DK-340 Birkerød

Certified Advisor

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, Email:

About ViroGates

ViroGates is an international medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 500 clinical trials and studies which included more than 300,000 blood samples.

Attachment

EN
25/04/2019

Underlying

VIROViroGates

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ViroGates

 PRESS RELEASE
Free
VIRO VIROGATES

ViroGates Releases Third Quarter 2019 Results

ViroGates Releases Third Quarter 2019 Results Company announcement no. 13-2019                                                                                            Birkerød, 28 October 2019 ViroGates A/S (Nasdaq First North Growth Market Denmark: VIRO), who delivers blood test systems for emergency departments in hospitals, today reported financial results for the third quarter 2019 (1 July – 30 September). Highlights in the third quarter of 2019 Financial highlights Revenue fell by 33% to TDKK 551 (TDKK 824 in Q3 2018)Net operating expenses of TDKK 4,700 (TDKK 3,551 in Q3 2018...

October 28, 2019 1 EN
 PRESS RELEASE
Free
VIRO VIROGATES

ViroGates announces clinical implementation of suPARnostic® TurbiLate...

ViroGates announces clinical implementation of suPARnostic® TurbiLatex at University Hospital of Montpellier France Company announcement no. 12-2019    Birkerød, 3 September 2019   ViroGates A/S (Nasdaq First North Growth Market Denmark: VIRO), who delivers blood test systems, primarily for acute care departments in hospitals, today announces that suPARnostic® now will be available for clinical decision making in the University Hospital of Montpellier, France. The hospital will be the first hospital in the world to run suPARnostic® TurbiLatex at the Roche cobas 8000 system. ...

September 3, 2019 1 EN
 PRESS RELEASE
Free
VIRO VIROGATES

ViroGates and QIAGEN announces a partnership to launch suPARnostic® Q...

ViroGates and QIAGEN announces a partnership to launch suPARnostic® Quick Triage on QIAGEN’s automated Lateral Flow (aLF) platform Company announcement 11-2019 Birkerød, Denmark and Hilden, Germany, 27 August 2019 ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems, primarily for emergency departments in hospitals, today announces that it has entered into a distribution and license agreement with QIAGEN under which ViroGates will act as an appointed distributor for QIAGEN of the aLF reader (). ViroGates has completed a validation of the instrument fo...

August 27, 2019 1 EN
 PRESS RELEASE
Free
VIRO VIROGATES

ViroGates Releases Second Quarter 2019 Results

ViroGates Releases Second Quarter 2019 Results Company announcement no. 10-2019 Birkerød, 21 August 2019 ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems for emergency departments in hospitals, today reported financial results for the second quarter 2019 (1 April – 30 June). Highlights in the second quarter of 2019 Financial highlights Revenue grew by 34% to TDKK 1,465 (TDKK 1,092 in Q2 2018)Net operating expenses of TDKK 5,948 (TDKK 10,333 in Q2 2018)Net result of TDKK -4,349 (TDKK -8,724 in Q2 2018)Cash position of TDKK 50,165 per 30 June 20...

August 21, 2019 1 EN
 PRESS RELEASE
Free
VIRO VIROGATES

ViroGates appoints Mark Christian Hvidberg da Silva as its new CFO

ViroGates appoints Mark Christian Hvidberg da Silva as its new CFO Company announcement no. 9-2019                                                                                              Birkerød, 14 August 2019 ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems, primarily for acute care departments in hospitals, today announces that Mark Christian Hvidberg da Silva will be joining ViroGates as the Company’s new CFO. The former CFO, May Britt Dyvelkov will remain with ViroGates in a new position as Vice President of Accounting. Mark is 29 years old and...

August 14, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch